Spyre Therapeutics Inc (SYRE) USD0.0001

Sell:$9.15Buy:$22.79$0.64 (4.40%)

NASDAQ:0.52%
Market closed | Prices delayed by at least 15 minutes
Sell:$9.15
Buy:$22.79
Change:$0.64 (4.40%)
Market closed | Prices delayed by at least 15 minutes
Sell:$9.15
Buy:$22.79
Change:$0.64 (4.40%)
Market closed | Prices delayed by at least 15 minutes

Company Information

About this company

Spyre Therapeutics, Inc. is a clinical-stage biotechnology company, which is engaged in creating inflammatory bowel disease (IBD) and other immune-mediated disease products by combining antibody engineering, rational therapeutic combinations and precision medicine approaches. Its pipeline includes investigational extended half-life antibodies targeting a4b7, TL1A, and IL-23. Its pipeline programs include SPY003, SPY004, SPY130, SPY230, SPY002, SPY001, and SPY120. Its advanced product candidate, SPY001, is a fully human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4b7 integrin being developed for the treatment of IBD. Its co-lead program, SPY002, has nominated two fully human mAb candidates designed to bind to tumor necrosis factor-like ligand 1A (TL1A), both of which are in preclinical development for the treatment of IBD. SPY003 is a preclinical-stage program designed to bind to Interleukin 23 (IL-23) and incorporates half-life extending modifications.

Key people

Cameron Turtle
Chief Executive Officer, Director
Scott L. Burrows
Chief Financial Officer
Sheldon Sloan
Chief Medical Officer
Heidy Abreu King-Jones
Chief Legal Officer, Corporate Secretary
Jeffrey W. Albers
Independent Chairman of the Board
Mark C. Mckenna
Director
Peter Harwin
Independent Director
Michael Henderson
Independent Director
Tomas Kiselak
Independent Director
Click to see more

Key facts

  • EPIC
    SYRE
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US00773J2024
  • Market cap
    $893.23m
  • Employees
    65
  • Shares in issue
    60.35m
  • Exchange
    NASDAQ
  • Index
    TR Equity United States Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.